Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 13/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2790708 | 0.87 | EPHX2 (1.00) | EPHX2CYP2C9 | |
| SCHEMBL3474360 | 0.87 | EPHX2 (0.63) | EPHX2CYP2C9 | |
| SCHEMBL2260526 | 0.85 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2260321 | 0.85 | EPHX2 (0.84) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL3471782 | 0.85 | EPHX2 (0.79) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL3474826 | 0.83 | EPHX2 (0.76) | EPHX2CYP2C9 | |
| SCHEMBL2261854 | 0.82 | EPHX2 (1.00) | EPHX2CYP2C9 | |
| SCHEMBL2259128 | 0.81 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2259994 | 0.81 | EPHX2 (0.87) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2260201 | 0.81 | EPHX2 (0.86) | EPHX2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | claimed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | EPHX2 5/4885CYP2C9 201/4885CYP3A4 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.